Lupin rose 0.98% to Rs 1011.95 at 14:12 IST on BSE after consolidated net profit surged 35.51% to Rs 553 crore on 20.67% growth in total income from operations to Rs 3120.53 crore in Q4 March 2014 over Q4 March 2013.
The Q4 result was announced during trading hours today, 7 May 2014.
Meanwhile, the S&P BSE Sensex was down 123.85 points or 0.55% at 22,384.57.
On BSE, so far 1.39 lakh shares were traded in the counter, compared with an average daily volume of 56,229 shares in the past one quarter.
The stock was volatile. The stock rose as much as 1.98% at the day's high of Rs 1022 so far during the day, which is a record high for the counter. The stock lost as much as 0.81% at the day's low of Rs 994 so far during the day. The stock had hit a 52-week low of Rs 695.10 on 6 May 2013.
The stock had outperformed the market over the past one month till 6 May 2014, advancing 2.68% compared with the Sensex's 0.67% rise. The scrip had, however, underperformed the market in past one quarter, advancing 10.27% as against Sensex's 10.82% rise.
More From This Section
The large-cap company has equity capital of Rs 89.69 crore. Face value per share is Rs 2.
Lupin's consolidated net profit rose 39.73% to Rs 1836.37 crore on 25.5% growth in total income from operations to Rs 8939.38 crore in the year ended 31 March 2014 (FY 2014) over the year ended 31 March 2013 (FY 2013).
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally.
Powered by Capital Market - Live News